Two-thirds of the public say they are very or somewhat worried about being told they have the disease—higher than for any other medical condition, including dementia and having a heart attack—according to polling.
Jul 14, 2024
0
60
A new drug could offer a powerful way to sensitize tumors to immunotherapy, a new trial suggests. The results have been published in the Journal of Clinical Investigation.
Feb 27, 2024
0
53
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
50
Men with hormone-resistant prostate cancer and specific genetic mutations who were treated with the PARP inhibitor drug olaparib survived longer than men treated with traditional hormone therapy, according to an analysis ...
Dec 7, 2023
0
37
Immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab improved progression-free survival (PFS) in patients with newly diagnosed advanced or recurrent endometrial cancer compared with chemotherapy alone, with further ...
Oct 23, 2023
0
42
New research, published in Nature Genetics, shows that more people may benefit from PARP inhibitor drugs, like olaparib, which are already used to treat some breast, ovarian and prostate cancer patients who have inherited ...
Aug 1, 2023
0
70
The U.S. Food and Drug Administration approved Lynparza (olaparib) with abiraterone and prednisone (or prednisolone) for adult patients with deleterious or suspected deleterious BRCA-mutated, metastatic, castration-resistant ...
Jun 7, 2023
0
68
In the five years since the FDA's initial approval of chimeric antigen receptor (CAR) T cell therapy, Penn Medicine has gleaned 20 additional approvals related to drugs and techniques to treat or detect cancer.
May 29, 2023
0
106
Routine diagnostic analyses of mutations in cell-free DNA in patients with metastatic prostate cancer are now possible for the first time in Sweden. The test has been developed by researchers at Karolinska Institutet, and ...
Apr 27, 2023
0
36
A combination of the PARP inhibitor olaparib (Lynparza) and the investigational ATR inhibitor ceralasertib showed clinical benefit in pediatric patients with solid tumors exhibiting DNA replication stress and/or DNA repair ...
Apr 18, 2023
0
59
